Neisvac-C

N. meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid A, the active ingredient in Neisvac-C, is a vaccine presented as a vaccine for intramuscular use. It is used to prevent invasive disease caused by Neisseria meningitidis serogroup C, primarily in children, adolescents and adults at risk.

GNH USA supplies Neisvac-C as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neisvac-C is a meningococcal group C conjugate vaccine indicated for prevention of invasive disease caused by Neisseria meningitidis serogroup C. - Invasive meningococcal disease: provides active immunity to reduce the risk of meningitis and septicemia caused by serogroup C. - Outbreak control: used in mass vaccination campaigns to curb serogroup C outbreaks. - Travel to endemic areas: protects travelers visiting regions where serogroup C is prevalent.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: transient low‑grade temperature rise. - Headache or fatigue: mild systemic symptoms.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder. - Seizures: infrequent neurologic event post‑vaccination.

Neisvac-C should be administered only after evaluating individual risk factors. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Breastfeeding: generally considered safe, but weigh benefits against any unknown risks. - Immunocompromised individuals: vaccine may elicit a reduced immune response. - Prior severe allergic reaction to any vaccine component: contraindicates further doses. - Age: recommended for individuals from 2 months of age onward according to local immunisation schedules. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccination timing may need adjustment when other agents are used. Major Interactions (Avoid): - Live viral vaccines: avoid simultaneous administration as immune interference may occur. - Immunoglobulin therapy: may neutralise the vaccine antigen and reduce efficacy. Moderate Interactions (Monitor Closely): - Antipyretics (e.g., acetaminophen, ibuprofen): may reduce fever but do not significantly affect immunogenicity. - Immunosuppressive drugs (e.g., corticosteroids, chemotherapy): may diminish antibody response. - Blood products or plasma: may interfere with vaccine‑induced immunity if given shortly before or after vaccination.